Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Homo sapiens | SMAD family member 2 | Starlite/ChEMBL | No references |
Species | Potential target | Known druggable target/s | Ortholog Group |
---|---|---|---|
Brugia malayi | MH2 domain containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | MH2 domain-containing protein | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Loa Loa (eye worm) | transcription factor SMAD2 | Get druggable targets OG5_131716 | All targets in OG5_131716 |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Brugia malayi | MH2 domain containing protein | SMAD family member 2 | 467 aa | 405 aa | 31.6 % |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | endoprotease bli-4 | 0.0496 | 1 | 1 |
Loa Loa (eye worm) | transcription factor SMAD2 | 0.0144 | 0.0711 | 0.0711 |
Brugia malayi | neuroendocrine convertase 1 precursor | 0.0312 | 0.5135 | 0.4763 |
Giardia lamblia | High cysteine membrane protein Group 2 | 0.0184 | 0.1773 | 0.5 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0302 | 0.4865 | 1 |
Echinococcus multilocularis | neuroendocrine convertase 2 | 0.0312 | 0.5135 | 0.6877 |
Loa Loa (eye worm) | MH2 domain-containing protein | 0.0144 | 0.0711 | 0.0711 |
Trichomonas vaginalis | Clan SB, family S8, subtilisin-like serine peptidase | 0.0302 | 0.4865 | 1 |
Echinococcus multilocularis | 0.04 | 0.7468 | 1 | |
Loa Loa (eye worm) | hypothetical protein | 0.0496 | 1 | 1 |
Schistosoma mansoni | furin-1 (S08 family) | 0.0216 | 0.2603 | 0.2603 |
Schistosoma mansoni | subfamily S8B unassigned peptidase (S08 family) | 0.0496 | 1 | 1 |
Brugia malayi | celfurPC protein | 0.04 | 0.7468 | 0.7274 |
Loa Loa (eye worm) | hypothetical protein | 0.0195 | 0.2043 | 0.2043 |
Brugia malayi | proprotein convertase 2 | 0.0312 | 0.5135 | 0.4763 |
Echinococcus granulosus | neuroendocrine convertase 2 | 0.0312 | 0.5135 | 0.5135 |
Echinococcus multilocularis | proprotein convertase subtilisin:kexin type 5 | 0.0302 | 0.4865 | 0.6515 |
Echinococcus granulosus | proprotein convertase subtilisin:kexin type 5 | 0.0302 | 0.4865 | 0.4865 |
Echinococcus granulosus | furin | 0.0496 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Potency (functional) | 11.2202 uM | PUBCHEM_BIOASSAY: qHTS for Inhibitors of TGF-b. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID588856, AID588860] | ChEMBL. | No reference |
Potency (functional) | 29.0929 uM | PubChem BioAssay. A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: Inhibitors of the vitamin D receptor (VDR): qHTS. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504855] | ChEMBL. | No reference |
Potency (functional) | 44.6684 uM | PUBCHEM_BIOASSAY: HTS for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488962] | ChEMBL. | No reference |
Potency (functional) | 50.1187 uM | PubChem BioAssay. qHTS of PTHR Inhibitors: Primary Screen. (Class of assay: confirmatory) | ChEMBL. | No reference |
Potency (functional) | 79.4328 uM | PUBCHEM_BIOASSAY: qHTS Assay for Inhibitors of JMJD2A-Tudor Domain. (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID504402] | ChEMBL. | No reference |
Potency (functional) | 89.1251 uM | PUBCHEM_BIOASSAY: qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1). (Class of assay: confirmatory) [Related pubchem assays (depositor defined):AID488813] | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.